Kidada Gilbert-Lewis, MD
Cytopathology · Houston, TXNPI 1194916379
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $525, 5.2 times the $100 reported in 2020.
Across 11 payments — averaging $75.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$179
- Sanofi$140
- AstraZeneca$125
- Janssen Scientific Affairs, LLC$121
- Neurocrine Biosciences, Inc.$109
- Otsuka Pharmaceutical Development & Commercialization, Inc.$100
- plus $54 from 2 others
What the payments were for
- Food & beverage$828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $179 |
| Sanofi | 1 | $140 |
| AstraZeneca | 2 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Neurocrine Biosciences, Inc. | 1 | $109 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| Agilent Technologies, Inc. | 1 | $37 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$828 in reported general payments places this provider in the 80th percentile of 24 cytopathology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cytopathology in Houston
- Neda KalhorHouston$30K
- William SymmansHouston$9K
- Linda GreenHouston$223
- Ming GuoHouston$176
- Yun GongHouston$86
- Xiao HuangHouston$86
- Christina FanningHouston$72
- John StewartHouston$39
- Gordana VerstovsekHouston$14
- Luis de Las CasasDallas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.